Richmond-based Health Diagnostics Laboratory, Inc., known for its heart disease and diabetes early-detection tests, is expanding. HDL has acquired the American subsidiary of Oncimmune, a U.K.-based company that produces early cancer detection tests. While the deal only applies to its lung cancer test, "of course HDL is interested in Oncimmune's pipeline of disease risk detection products," says Jeff Kelley, the marketing program manager for HDL (who is also a regular Richmond magazine contributor). This deal makes the company the exclusive American provider of the lung cancer test.
